Key Highlights

  • Pluri (NASDAQ:PLUR) traded about 16.16% higher near USD 1.15 in early trading on Monday, October 26, 2026, after announcing a definitive partnership with ZEO ScientifiX, Inc. that day.
  • Pluri (NASDAQ:PLUR) is expected to own 50% of ZEO ScientifiX at closing in exchange for manufacturing technology rights, with ZEO's financials to be consolidated into Pluri's accounts.
  • ZEO ScientifiX receives exclusive U.S. rights to the Cellav aesthetics product line of Pluri, while Pluri retains ownership of the underlying technology and intellectual property.
  • Closing is expected in the fourth quarter of 2026, subject to ancillary agreements, approvals and valuations, and neither company's shareholders need to vote on the agreement.

Pluri (NASDAQ:PLUR): a U.S. platform partnership with ZEO ScientifiX

Pluri (NASDAQ:PLUR), a cell-based technology company listed on Nasdaq and the Tel Aviv Stock Exchange, traded about 16.16% higher near USD 1.15 in early trading on Monday, October 26, 2026. The company announced on that day a definitive agreement with ZEO ScientifiX, Inc. (OTCQB: ZEOX) to expand a U.S. manufacturing and commercial platform for regenerative medicine, aesthetics, wellness and longevity. ZEO will contribute biologics manufacturing, an existing product portfolio, physician relationships and sales resources. Pluri will contribute cell-based product development, clinical experience and its proprietary three-dimensional cell expansion platform, backed by over 200 patents. The release cited multinational Phase III trials in muscle recovery after hip fracture surgery and in critical limb ischemia. The price is an intraday figure.

How the Deal Works for Pluri (NASDAQ:PLUR)

Pluri (NASDAQ:PLUR) grants ZEO defined rights to its manufacturing technology and related know-how for regenerative medicine assets, and keeps ownership of the technology and intellectual property. In exchange, ZEO will issue common stock equal to 50% of its outstanding common stock immediately after closing, together with warrants and governance and protective rights. Because Pluri is expected to hold 50% and ZEO's results are to be consolidated, revenue and costs of ZEO would appear in Pluri's accounts. Consolidation means a parent reports a subsidiary's full financials. Pluri also grants ZEO exclusive U.S. rights to Cellav, its wholly owned aesthetics subsidiary, including future offerings. The structure gives Pluri access to a U.S. sales network without building one.

Risks and What to Watch

The risks for Pluri (NASDAQ:PLUR) are failure to close, integration of ZEO, further funding needs, clinical and commercial setbacks and manufacturing problems, all of which the release itself flagged. Closing depends on ancillary agreements, certain approvals and valuation deliveries, with completion expected in the fourth quarter of 2026. A separate release of Wednesday, October 21, 2026 said that chairman Alejandro Weinstein would acquire a loan from the European Investment Bank, which concerns the company's debt arrangements. ZEO trades on the OTCQB, a lightly regulated market with thinner liquidity. Investors should watch closing steps, the ZEO valuation, the next quarterly report and the Fed decision on Wednesday, October 28, 2026.

Where Things Stand

The answer is that Pluri (NASDAQ:PLUR) rose about 16.16% in early trading on Monday, October 26, 2026 on the announcement of a definitive partnership under which it is expected to own 50% of ZEO ScientifiX and consolidate its financials, with closing expected in the fourth quarter of 2026. The shares trade near USD 1.15 on an intraday basis. The next catalysts are signing of the ancillary agreements, the receipt of approvals, the valuation and the Fed decision on Wednesday, October 28, 2026. Closing is not assured, small biotechnology shares are volatile, and this is not investment advice.